RNA Polypeptide Vaccine Kit for Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA-based vaccines face safety concerns regarding integration into the host genome and potential uncontrolled propagation, while RNA vaccines are susceptible to degradation and lack efficient cellular uptake.
Innovation Solution
The development of immunogenic compositions comprising a self-replicating RNA molecule encoding a polypeptide antigen and a separate polypeptide antigen, delivered in a kit format for sequential administration, enhances immune response by providing antigenic epitopes in both RNA and polypeptide forms, potentially using alphavirus-derived RNA replicons and adjuvants like MF59.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based vaccines are used, then cellular immune response is generated, but safety concerns arise regarding integration into host genome and uncontrolled propagation
Solution Approach 1:
The patent extracts the antigen-encoding sequence from the DNA vaccine context and transfers it to an RNA-based delivery system. By using RNA instead of DNA, the invention eliminates the risk of genomic integration while maintaining the ability to induce cellular immune responses through expression of the antigen in antigen-presenting cells.
Solution Approach 2:
The invention changes the fundamental parameter of the genetic material from DNA to RNA. This parameter change resolves the safety concern about genomic integration, as RNA does not integrate into the host genome like DNA can. The RNA is transient and degrades naturally, providing a safer alternative while maintaining immunogenicity.
2Ease of operation
If RNA vaccines are used, then degradation susceptibility increases, but cellular uptake efficiency improves
Solution Approach 1:
The patent employs an adjuvant as an intermediary substance that facilitates the delivery and stabilization of RNA in the vaccine composition. The adjuvant protects the RNA from degradation while enhancing its cellular uptake and immunogenicity, effectively resolving the contradiction between RNA stability and cellular uptake efficiency.
Solution Approach 2:
The invention creates a composite vaccine composition combining RNA with adjuvants. This composite formulation provides both the benefits of RNA (transient expression, safety) and the stabilizing effects of adjuvants, while also enhancing cellular uptake and immune response.
3Quantity of substance
If only RNA component is administered, then antigen expression is achieved, but antibody titers are insufficient
Solution Approach 1:
The patent merges two immunogenic components into a single vaccine composition: RNA encoding an antigen and a separate antigen or adjuvant. This combination synergistically enhances the immune response, producing higher antibody titers and more robust cellular immunity than RNA alone, while maintaining the safety advantages of RNA-based delivery.
4Ease of manufacture
If DNA vaccine is used, then manufacturing simplicity is maintained, but safety concerns regarding uncontrolled propagation arise
Solution Approach 1:
The invention extracts the antigen-encoding sequence from the DNA context and implements it in an RNA-based system. This extraction eliminates the propagation risks associated with DNA while preserving the manufacturing advantages of using a nucleic acid-based platform that can be produced through established in vitro transcription methods.
Data Source
AI summary
This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.